Pharmaceutical intelligence for King Pharmaceuticals with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Assets: 3

Recent signals(2)

RegulatoryAugust 6, 2026

FDA Submission Update for ALTACE (Ramipril) by King Pharmaceuticals

King Pharmaceuticals has submitted a supplemental application for ALTACE (Ramipril) with a standard review priority.

RegulatoryJuly 1, 2026

FDA Approves Supplement for Bicillin L-A by King Pharmaceuticals

The FDA has granted approval for a supplemental application for Bicillin L-A, containing Penicillin G Benzathine.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

RegulatoryAugust 6, 2026

FDA Submission Update for ALTACE (Ramipril) by King Pharmaceuticals

King Pharmaceuticals has submitted a supplemental application for ALTACE (Ramipril) with a standard review priority.

RegulatoryJuly 1, 2026

FDA Approves Supplement for Bicillin L-A by King Pharmaceuticals

The FDA has granted approval for a supplemental application for Bicillin L-A, containing Penicillin G Benzathine.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

ALTACE (Ramipril) →

FDA →

Regulatory Approval →

Therapeutic areas

Infectious Disease · Antibiotic →

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.